A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
National Cancer Institute (NCI)
Neonc Technologies, Inc.
Merck Sharp & Dohme LLC
AIDS Malignancy Consortium
City of Hope Medical Center